FDA Panel Backs Grail Galleri Cancer Test
Analysis based on 18 articles · First reported Sep 23, 2026 · Last updated Sep 24, 2026
The recommendation lifts prospects for Grail and validates the multi-cancer early detection sector, potentially unlocking Medicare and private insurance reimbursement that could sharply expand the market. It also raises competitive stakes for rivals such as Abbott Laboratories, whose competing CancerGuard test is pursuing FDA approval, while broader diagnostic and life sciences names may see sentiment spillover.
An advisory committee to the United States — Food and Drug Administration voted on Wednesday to recommend approval of Grail Inc.'s Galleri blood test, the first multi-cancer early detection test to reach this stage of federal review. The panel voted 7-2 with one abstention that the DNA-based test's potential benefits outweigh its risks, following earlier votes affirming the test appears safe and effective for people age 50 and older. The Galleri test uses a single blood draw to look for signals of more than 50 cancers, including many with no routine screening options such as liver, ovarian and pancreatic cancer. Grail's studies, including a UK United Kingdom — National Health Service trial of over 140,000 patients and a North American study of more than 35,000, showed the test detected roughly one third of cancers diagnosed within a year, and about two thirds of positive results were later confirmed as cancer. Panelists and FDA reviewers raised concerns that the test missed two of three cancers, was less accurate for early-stage disease, and lacked data showing reduced cancer deaths. The FDA is not bound by the recommendation but typically follows it; a final decision is expected in a few months. Approval would open the door to Medicare coverage beginning in 2028 under legislation Grail lobbied for, and could spur private insurer reimbursement for the $949 test. The vote is seen as a bellwether for a crowded field of companies pursuing multi-cancer detection tests, including Abbott Laboratories' CancerGuard.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard